U.S. FDA orders Pfizer to test 2nd Paxlovid course for rebound COVID patients – National

Posted on

The U.S. Food and Drug Administration (FDA) has ordered Pfizer Inc PFE.N to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.

The drugmaker must produce initial results of a randomized controlled trial of a second course of the antiviral by Sept. 30 next year, the FDA told Pfizer in a letter dated Aug. 5.

Read more: Health Canada approves 1st COVID-19 booster for kids 5-11

The regulator said a formal plan for the clinical trial is expected to be finalized this month.

Pfizer is “working with the FDA to finalize a protocol to study patients who may be in need of retreatment,” and will provide details when available, a company spokesperson said.

Story continues below advertisement

(Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)

Jasaseosmm.com Smm Panel is the best and cheapest smm reseller panel Buy Facebook Verification for instant Instagram likes and followers, Buy Verification Badge, Youtube views and subscribers, TikTok followers, telegram services, and many other smm services. telegram, and many other smm services